Alaunos Therapeutics, Inc. (TCRT) Key Metrics
TCRT valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $7.7M
- Enterprise value
- $2.9M
- P/E (TTM)
- —
- Forward P/E
- 18.5
- PEG ratio
- 0.58
- Price / sales
- — 10-yr median 101.7
- Price / book
- 4.6 10-yr median 3.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.87
TCRT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTCRT valuation Price multiples at each fiscal year-end price.
Price / book+97.2%
2.9
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+115.4 pts
−47.1%
2025 · hover or tap a bar for each year
20162025
TCRT returns How much profit the business earns on the capital it uses.
Return on equity−86.3 pts
−198.1%
2025 · hover or tap a bar for each year
20162025
Return on invested capital+241.1 pts
−383.6%
2025 · hover or tap a bar for each year
20162025
Return on assets−61.1 pts
−146.0%
2025 · hover or tap a bar for each year
20162025
Asset turnover−3.7%
0.00
2025 · hover or tap a bar for each year
20162025
TCRT per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−58.9%
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$2.14
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.52
2025 · hover or tap a bar for each year
20162025
Book value per share−14.2%
$1.11
2025 · hover or tap a bar for each year
20162025
Shares outstanding+21.7%
1.9M
2025 · hover or tap a bar for each year
20162025
TCRT financial health Debt, liquidity and how easily interest is covered.
Net debt−$294,000
−$1.4M
2025 · hover or tap a bar for each year
20162025
Current ratio−38.6%
2.45
2025 · hover or tap a bar for each year
20162025
TCRT efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+182 days
292 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−420 days
151 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+602 days
141 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+1,960.0 pts
1,960.0%
2025 · hover or tap a bar for each year
20162025
TCRT valuation history
Fiscal year-endToday10-year median
TCRT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TCRT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TCRT cash returned to shareholders
DividendsBuybacksFree cash flow
TCRT price vs earnings per share
Share price at year-endEPS (right axis)
TCRT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $6.3M | $3.1M | $16.8M | $141.1M | $233.7M | $528.3M | $792.7M | $268.4M | $566.9M | $697.6M |
| Enterprise value | $4.9M | $2.0M | $10.7M | $122.1M | $187.7M | $418.0M | $715.3M | $206.6M | $496.0M | $616.5M |
| Price / sales | — | 305.8 | — | 48.3 | 587.2 | — | — | — | 88.7 | 101.7 |
| Price / book | 2.9 | 1.5 | 2.7 | 3.7 | 4.0 | 4.3 | 8.3 | 3.1 | — | — |
| EV / sales | 981.6 | 196.7 | — | 41.8 | 471.7 | — | — | — | 77.6 | 89.9 |
| Earnings yield | −66.4% | −153.0% | −209.2% | −26.7% | −33.7% | −14.9% | −14.9% | −19.8% | −9.6% | −23.7% |
| Free cash flow yield | −47.1% | −162.5% | −180.6% | −20.9% | −27.7% | −12.6% | −5.2% | −18.6% | −9.8% | −8.4% |
| Dividend yield | — | — | — | — | — | — | — | 6.3% | — | 1.0% |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 6.9% | 0.4% | 1.2% |
| Share price at fiscal year-end | $3.23 | $1.91 | $10.50 | $97.50 | $163.50 | $378.00 | $708.00 | $280.50 | $621.00 | $802.50 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.01 | $0.00 | $2.02 | $0.28 | $0.00 | $0.00 | $0.15 | $7.00 | $7.89 |
| Earnings per share | −$2.14 | −$2.92 | −$21.97 | −$26.07 | −$55.10 | −$56.42 | −$105.21 | −$55.52 | −$59.50 | −$190.15 |
| Operating cash flow per share | −$1.47 | −$3.10 | −$18.84 | −$20.19 | −$43.00 | −$40.79 | −$36.49 | −$51.69 | −$59.88 | −$67.10 |
| Free cash flow per share | −$1.52 | −$3.10 | −$18.97 | −$20.34 | −$45.33 | −$47.79 | −$36.74 | −$52.17 | −$60.69 | −$67.73 |
| Cash per share | $0.71 | $0.68 | $3.79 | $26.98 | $53.21 | $82.33 | $71.22 | $64.52 | $77.71 | $93.24 |
| Book value per share | $1.11 | $1.29 | $3.94 | $26.63 | $40.62 | $88.71 | $84.85 | $89.43 | −$106.04 | −$88.92 |
| Tangible book value per share | $1.11 | $1.29 | $3.94 | $26.63 | $40.62 | $88.71 | $84.85 | $89.43 | −$106.04 | −$88.92 |
| Dividends per share | — | — | — | — | — | — | — | $17.77 | — | $8.19 |
| Capex per share | $0.05 | $0.00 | $0.12 | $0.15 | $2.32 | $7.00 | $0.25 | $0.48 | $0.81 | $0.63 |
| Debt per share | — | — | — | $13.86 | $21.05 | $3.44 | $2.10 | — | — | — |
| Shares outstanding | 1.9M | 1.6M | 1.6M | 1.4M | 1.4M | 1.4M | 1.1M | 957K | 913K | 869K |
| Change in shares outstanding | +21.7% | +0.1% | +10.5% | +1.3% | +2.3% | +24.8% | +17.0% | +4.8% | +5.0% | +4.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −198.1% | −111.8% | −156.7% | −78.1% | −86.5% | −72.0% | −130.5% | — | — | — |
| Return on invested capital (ROIC) | −383.6% | −624.7% | −273.3% | −175.2% | −474.5% | −405.0% | −220.5% | — | — | — |
| Return on assets (ROA) | −146.0% | −84.9% | −96.0% | −47.2% | −65.3% | −61.7% | −115.4% | −52.9% | −51.3% | −127.1% |
| Return on tangible assets | −140.8% | −169.8% | −425.3% | −58.1% | −83.0% | −53.9% | −108.0% | −55.9% | −51.4% | −155.4% |
| Free cash flow margin | — | — | — | — | — | — | — | — | −867.2% | −858.1% |
| Financial health | ||||||||||
| Total debt | — | — | — | $20.1M | $30.1M | $4.8M | $2.4M | — | — | — |
| Cash & short-term investments | $1.4M | $1.1M | $6.1M | $39.1M | $76.1M | $115.1M | $79.7M | $61.7M | $70.9M | $81.1M |
| Net debt | −$1.4M | −$1.1M | −$6.1M | −$19.0M | −$46.0M | −$110.3M | −$77.4M | −$61.7M | −$70.9M | −$81.1M |
| Debt / equity | — | — | — | 0.52 | 0.52 | 0.04 | 0.02 | — | — | — |
| Debt / assets | — | — | — | 0.31 | 0.32 | 0.03 | 0.02 | — | — | — |
| Current ratio | 2.45 | 3.98 | 4.22 | 2.23 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 |
| Quick ratio | 2.45 | 3.98 | 4.22 | 1.65 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 |
| Interest coverage | — | — | -17.8 | -11.1 | -65.2 | -208.7 | -0.5 | -68.3 | -64.4 | — |
| Working capital | $1.2M | $2.1M | $6.3M | $29.6M | $62.8M | $112.2M | $93.0M | $74.8M | $69.9M | $89.1M |
| Invested capital | $768,000 | $972,000 | $245,000 | $19.6M | $12.1M | $13.7M | $17.6M | $23.8M | −$167.8M | −$158.4M |
| Tangible asset value | $2.2M | $2.1M | $6.3M | $38.6M | $58.1M | $124.0M | $95.0M | $85.6M | −$96.8M | −$77.3M |
| Net current asset value | $1.2M | $2.1M | $6.3M | $27.4M | $42.0M | $108.2M | $91.4M | $74.8M | −$111.6M | −$78.8M |
| Graham net-net per share | $0.29 | $0.25 | $2.57 | $13.57 | $28.04 | $68.84 | $60.85 | $56.07 | −$143.99 | −$118.00 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $17.0M | — | $7.1M |
| Share buybacks (net) | — | — | $0 | $45,000 | $0 | $283,000 | $653,000 | $1.6M | $2.1M | $1.5M |
| Capex / revenue | 1,960.0% | 0.0% | 3,940.0% | 7.4% | 834.9% | — | — | 314.4% | 11.5% | 8.0% |
| Capex / depreciation | 14.00 | 0.00 | 0.09 | 0.08 | 1.28 | 8.67 | 0.45 | 0.80 | 2.00 | 1.90 |
| Stock-based compensation / revenue | 8,280.0% | 4,350.0% | 56,000.0% | 120.7% | 2,707.0% | — | — | 5,160.3% | 132.3% | 123.2% |
| R&D / revenue | 27,260.0% | 3,620.0% | 325,580.0% | 856.2% | 12,473.1% | — | — | 23,379.5% | 705.7% | 2,299.8% |
| SG&A / revenue | 57,340.0% | 44,600.0% | 244,380.0% | 449.8% | 6,601.8% | — | — | 13,642.5% | 231.6% | 209.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 292.0 | 109.5 | 182.5 | 69.6 | 2,648.5 | — | — | 2,353.8 | 1.1 | 12.4 |
| Days of inventory on hand | — | — | — | 225.9 | — | — | — | — | — | — |
| Days payables outstanding | 151.2 | 570.7 | 76.2 | 22.3 | 9.0 | 301.9 | 468.0 | — | — | — |
| Cash conversion cycle (days) | 140.8 | -461.2 | 106.3 | 273.2 | 2,639.6 | — | — | — | — | — |
| Receivables turnover | 1.25 | 3.33 | 2.00 | 5.24 | 0.14 | 0.00 | 0.00 | 0.16 | 319.45 | 29.38 |
| Payables turnover | 2.41 | 0.64 | 4.79 | 16.34 | 40.61 | 1.21 | 0.78 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | 1.62 | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.05 |
| Average receivables | $4,000 | $3,000 | $2,500 | $557,500 | $2.9M | $4.0M | $2.6M | $941,500 | $20,000 | $233,500 |
| Average payables | $564,500 | $566,000 | $1.0M | $1.4M | $1.2M | $933,000 | $806,500 | $2.6M | $2.3M | $1.1M |
| Average inventory | — | — | — | $13.9M | — | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TCRT's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TCRT valuation and financial ratios
Alaunos Therapeutics earned a return on equity of −198.1% and a return on invested capital of −383.6% in fiscal 2025. The share count rose 124.1% from 869K to 1.9M over 9 years.
See the TCRT income statement, the TCRT chart for price history, or the TCRT stock overview for the latest quote and news.
TCRT key metrics FAQ
What is Alaunos Therapeutics's return on equity?
Alaunos Therapeutics's return on equity (ROE) was −198.1% in fiscal 2025: net income of -$4.2 million on average shareholders' equity of $2.1 million.
What is Alaunos Therapeutics's ROIC?
Alaunos Therapeutics's return on invested capital was −383.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Alaunos Therapeutics's free cash flow yield?
Alaunos Therapeutics generated -$3.0 million of free cash flow in fiscal 2025, a free cash flow yield of −47.1% on its market value at year-end ($6.3 million).
What is Alaunos Therapeutics's current ratio?
Alaunos Therapeutics's current ratio was 2.45 at the end of fiscal 2025: current assets were 2.45 times current liabilities.